ELTX Stock Forecast & Price Target

Elicio Therapeutics is supported by a highly differentiated, off-the-shelf AMP vaccine platform that repeatedly generates strong, broad mKRAS-specific T-cell responses across diverse HLA backgrounds, with 99% response in the first 90 evaluable Phase 2 patients and 87.6% antigen spreading. Its lead asset, ELI-002 7P, has shown encouraging mechanistic validation even after the Phase 2 AMPLIFY-7P DFS miss, including a significant benefit in R0-resected patients and a safer, more scalable profile than personalized vaccines or small-molecule KRAS approaches. Financially, 2Q26 net loss was $0.43 per share, pro forma cash was about $37.5M after a ~$15M offering, and management expects funding into 1Q27, giving it runway to reach key late-2026 data and de-risk the pipeline further.

Elicio Therapeutics is burdened by a fragile IP position, because while its AMP platform has layered patent protection, much of the portfolio is still pending and MIT controls prosecution of six licensed patent families, leaving commercialization exposed to third-party decisions and potential Bayh–Dole constraints. Its lead asset, ELI-002 7P, still faces meaningful clinical and regulatory uncertainty in Phase 2 AMPLIFY DFS, despite prior Phase 1 signal in adjuvant PDAC, and any need for additional trials could delay revenue generation. Financially, the company is not yet profitable and may require additional equity financing before commercialization, with a cash runway extending through 4Q26, creating dilution risk and reinforcing a negative outlook.